A randomized phase 2 study of efmarodocokin alfa, an IL-22 agonist, versus vedolizumab in patients with ulcerative colitis.
Danese S, Rothenberg ME, Lim JJ, Ding HT, McBride JM, Chen Y, Dash A, Mar JS, Keir M, Peyrin-Biroulet L, Panes J, Colombel JF, Feagan B, Valentine JF, Schreiber S.
Danese S, et al. Among authors: peyrin biroulet l.
Clin Gastroenterol Hepatol. 2024 Dec 16:S1542-3565(24)01096-6. doi: 10.1016/j.cgh.2024.11.013. Online ahead of print.
Clin Gastroenterol Hepatol. 2024.
PMID: 39694207
Free article.